Clinical trials · Georgia
Multiple myeloma clinical trials in Georgia
We’re tracking 60 recruiting multiple myeloma studies with a site in Georgia — including Early Phase 1, Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies in Georgia
- NCT07227311RecruitingPhase 2
Belantamab mafodotin combinations for relapsed multiple myeloma
This trial tests a new drug called belantamab mafodotin (a targeted antibody therapy) combined with standard treatments for multiple myeloma that has come back or stopped responding. It looks at three different drug combinations to see which works best for people who have had 1 or 2 prior treatments.
Macon, GeorgiaAges 18 years+ - NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Atlanta, GeorgiaAges 18 years+ - NCT07073547RecruitingPhase 1
Study of AZD0120 for multiple myeloma patients
This trial tests a new drug, AZD0120, in people with multiple myeloma. It aims to find the right dose and see how safe and effective it is. The study includes both newly diagnosed and early relapsed patients.
Atlanta, GeorgiaAges 18 years+ - NCT06976476RecruitingPhase 2
IgPro20 to prevent infections in multiple myeloma patients on bispecific therapy
This study tests whether a weekly infusion of a blood product called IgPro20 can help prevent infections in people with multiple myeloma who are already being treated with a bispecific antibody. If you qualify, you will receive the study treatment and be monitored for safety and infection rates.
Atlanta, GeorgiaAges 18 years+ - NCT07681596RecruitingPhase 1/Phase 2
Study of a new drug for relapsed or refractory multiple myeloma
This trial tests an experimental drug for multiple myeloma that has come back or not responded to at least three previous treatments. It aims to see if the drug can help people whose cancer has progressed despite prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.
Atlanta, GeorgiaAges 18 years+ - NCT07116616RecruitingPhase 1/Phase 2
mRNA vaccine for relapsed or refractory multiple myeloma
This trial tests an experimental mRNA therapy called mRNA-2808 for people with multiple myeloma that has returned or stopped responding to prior treatments. It aims to see if it can help control the disease.
Atlanta, GeorgiaAges 18 years+ - NCT05850234RecruitingPhase 1/Phase 2
Study drug for hard-to-treat multiple myeloma after prior treatments
This Phase 1/2 study tests AZD0120 in people with multiple myeloma that has come back or is not responding to treatment. It may help by targeting the myeloma cells after you’ve already tried several standard therapies.
Atlanta, GeorgiaAges 18 years+ - NCT05862012RecruitingPhase 1
Test drug ISB 2001 in multiple myeloma patients who relapsed
This Phase 1 study tests ISB 2001, a new investigational treatment, in people with multiple myeloma that has come back or not responded to prior treatment. It mainly focuses on safety and whether the drug can be given effectively.
Atlanta, GeorgiaAges 18 years+ - NCT07391657RecruitingPhase 3
Comparing a new CAR-T therapy to standard treatments for multiple myeloma
This trial tests a new dual-targeted cell therapy (AZD0120) against standard regimens for people with multiple myeloma that has come back or not responded to treatment. It aims to see if the new therapy works better than standard options.
Atlanta, GeorgiaAges 18 years+ - NCT07222761RecruitingPhase 3
Comparing new treatments for relapsed multiple myeloma
This trial tests if a new medicine called linvoseltamab, alone or combined with carfilzomib, works better than the usual treatments for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior therapies.
Atlanta, GeorgiaAges 18 years+ - NCT07095452RecruitingPhase 2/Phase 3
Newly diagnosed myeloma: comparing drug combinations for non-transplant patients
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
Atlanta, GeorgiaAges 18 years+ - NCT06142396RecruitingEarly Phase 1
Dara-CyBorD for New Multiple Myeloma with Kidney Failure
This pilot study tests a combination of four drugs (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, known as Dara-CyBorD) in people newly diagnosed with multiple myeloma who also have kidney problems. The goal is to see if this treatment is safe and effective for this specific group.
Augusta, GeorgiaAges 18–80 - NCT05519085RecruitingPhase 3
Test mezigdomide vs pomalidomide with standard drugs for myeloma
This Phase 3 study compares two combination treatments for multiple myeloma that has come back or not gone away (relapsed or refractory). It aims to see whether mezigdomide, along with bortezomib and dexamethasone, works better than pomalidomide with those same medicines.
Athens, GeorgiaAges 18 years+ - NCT05243797RecruitingPhase 3
Teclistamab plus lenalidomide maintenance after transplant
This trial tests whether adding teclistamab to lenalidomide (or using teclistamab alone) helps keep newly diagnosed multiple myeloma from coming back after an autologous stem cell transplant. It’s comparing these options to lenalidomide alone as long-term maintenance.
Atlanta, GeorgiaAges 18 years+ - NCT07764978RecruitingPhase 3
New drug combo for multiple myeloma without stem cell transplant
This trial tests a new drug called AZD0120 added to standard treatments for people newly diagnosed with multiple myeloma who are not eligible for a stem cell transplant. It aims to see if the combination can better control the disease and improve outcomes.
Atlanta, GeorgiaAges 18 years+ - NCT06615479RecruitingPhase 3
New treatment vs standard care for relapsed multiple myeloma
This trial tests a new treatment called BMS-986393 (a type of CAR T-cell therapy) compared to standard treatments for adults with multiple myeloma that has come back or is not responding to therapy, and who have already been treated with lenalidomide (Revlimid). The goal is to see if the new treatment works better.
Atlanta, GeorgiaAges 18 years+ - NCT07393282RecruitingPhase 3
Comparing two treatments for high-risk smoldering multiple myeloma
This trial tests a new drug called linvoseltamab against an existing treatment, daratumumab, for people with a high-risk form of smoldering multiple myeloma. The goal is to see which one works better to delay or prevent the disease from becoming active multiple myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT07101445RecruitingPhase 4
Comparing steroids to prevent reactions to motixafortide in multiple myeloma
This trial tests two different steroid medicines (methylprednisolone and dexamethasone) to see which works better at preventing side effects from motixafortide, a drug used to help collect stem cells for a stem cell transplant in people with multiple myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT05640843Recruiting
Plant-based diet study for MGUS or smoldering myeloma
This trial tests whether a whole-food, plant-based eating pattern—plus supplements or placebo—can improve health outcomes in people with MGUS or smoldering multiple myeloma. You may be asked to follow specific recipes and stop certain supplements, so it helps to confirm you can stick with the plan.
Atlanta, GeorgiaAges 18 years+ - NCT05137054RecruitingPhase 1
Linvoseltamab combo for hard-to-treat multiple myeloma
This trial tests a new drug called linvoseltamab combined with other cancer treatments for people with multiple myeloma that has stopped responding to standard therapies. It may be an option if you have already tried several treatments and are looking for a new approach.
Atlanta, GeorgiaAges 18 years+ - NCT07053436RecruitingPhase 2
New treatment for high-risk myeloma before transplant
This study tests a new treatment combination for people with high-risk multiple myeloma who are newly diagnosed and healthy enough for a stem cell transplant. The goal is to see if the treatment can improve outcomes compared to standard therapy.
Atlanta, GeorgiaAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Atlanta, GeorgiaAges 18 years+ - NCT04776395RecruitingPhase 2
Iberdomide to treat intermediate or high-risk smoldering myeloma
This Phase 2 study tests iberdomide alone or with low-dose dexamethasone in people with intermediate- or high-risk “smoldering” multiple myeloma. The goal is to see if the treatment can control or delay progression to active myeloma.
Atlanta, GeorgiaAges 18 years+ - NCT03858205Recruiting
Low-dose radiation to relieve pain from bone tumors
This trial studies whether low-dose radiation can reduce pain from a specific bone lesion caused by multiple myeloma. It may help people whose main problem is painful bone metastasis, with targeted treatment to the painful spot.
Atlanta, GeorgiaAges 18 years+
Multiple myeloma trials by city in Georgia
Where these studies are running in Georgia
Institutions with a site for the recruiting multiple myeloma studies listed above.
- Emory University · 9 studies
- Research Site · 5 studies
- Winship Cancer Institute of Emory University · 2 studies
- Emory Healthcare
- Emory University (Data Collection Only)
- Emory University Winship Cancer Center
- Georgia Cancer Center-Augusta University
- GSK Investigational Site
What taking part in a multiple myeloma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Multiple myeloma trials in other states
Common questions
- Are there multiple myeloma clinical trials in Georgia?
- Yes. We're currently tracking 60 recruiting multiple myeloma studies with a site in Georgia, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a multiple myeloma study in Georgia?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Georgia to take part?
- Not necessarily. These studies have a site in Georgia, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New multiple myeloma studies open in Georgia regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.